Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biodel Inc (BIOD): Under $5 Biotech Stock on the Verge of a Potential 82% Breakout

Page 1 of 2

I like trading biotech stocks under $10. These little dynamos can be powerful wealth creation tools if wisely chosen and traded within a well-diversified portfolio.

I am sure I don’t need to say it to any experienced investors, but a word of caution is needed whenever mentioning biotech trading. Biotech stocks are notoriously volatile and can be an account killer if not managed with the utmost respect for risk.

Knowing which biotech stocks to buy and which to avoid is a science in and of itself. This process can become so complicated that often the best biotech investors are medical doctors or pharmaceutical research PhDs. These individuals can drill into the scientific nuances of the various biotech products to determine the ones that have a high chance of success.

Biodel Inc (NASDAQ:BIOD)

Well, what about the rest of us — those of us without high-level degrees in the sciences? Is success still possible trading biotech stocks?

I answer this question with an unequivocal yes. I have broken down the components of a successful biotech company into five easy-to-understand traits. While it is possible that a company possessing all five traits could still flop, it is a near certainty that if a biotech stock does not possess every one of the five traits, it will struggle to survive.

Here are the five traits every successful biotech company has:

Strong Management

This is perhaps the most important criteria. It is the management that makes the decisions on how to allocate the company’s resources for the best chance of success. Biotech managers need more than entrepreneurial zeal, they need scientific, pharmaceutical or medical backgrounds.

Manageable Debt

Correctly managed, debt can help a company navigate rough patches between funding. Mismanaged, debt will sink the company faster than the Titanic. Remember, the less debt the better when it comes to biotech companies.

Sufficient Funding

Along with low debt levels, successful biotech companies must have sufficient funding. Funding is what allows for research and will keep a company alive during the long, arduous drug approval process.

Multi-Product Pipeline

Avoid single-product companies. Companies with multiple drugs/products in the approval pipeline have a better chance of one of the products reaching the marketplace. While it is possible for a single-product firm to thrive, the odds are always better with multiple products.

Products Close to Launch

Investing in companies with products/drugs close to being approved will increase your odds of success. Avoid those firms with product approval a long way off. When I find a biotech stock with products not close to approval, rather than invest, I place it on a watch list for potential future investment.

Page 1 of 2
Loading Comments...